Home › NCT07157839
Phosphorylated Tau Levels in Donated Blood
Detection of Elevated Plasma pTau217 in Donated Human Blood Samples: Implications for Blood Transfusion Safety
Who can join
All ages · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * The plasma sample from donators. Exclusion Criteria: * None.
About the study
Alzheimer's disease (AD) is characterized by the accumulation of tau pathology, and blood-based biomarkers such as phosphorylated tau-217 (pTau217) have been identified as sensitive and specific predictors of AD risk. Recent studies suggest that individuals with elevated pTau217 levels may be at increased risk for developing AD and cognitive dysfunction. This observational study will examine donated human plasma samples to determine whether some units of donated blood contain abnormally elevated pTau217 concentrations. The overarching goal is to evaluate whether transfusion of blood with higher pTau217 may pose risks to recipients and whether such units should be avoided in clinical use.
Sponsor: The University of Texas Health Science Center, Houston · Participants: 250 · Started: Aug 28, 2025
Contact the study team
- Zhongcong Xie, M.D., Ph.D. · Phone: 17135006207
Official record on ClinicalTrials.gov — NCT07157839
Locations in the U.S.
| Texas | University of Texas Health Science Center at Houston, Houston |
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.